ImmunityBio Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Public

  • Employees
  • 691

Employees

  • Stock Symbol
  • IBRX

Stock Symbol

  • Investments
  • 8

  • Share Price
  • $6.01
  • (As of Friday Closing)

ImmunityBio General Information

Description

ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.

Contact Information

Website
www.immunitybio.com
Formerly Known As
NantCell, NantBioCell, Conkwest
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 3530 John Hopkins Court
  • San Diego, CA 92121
  • United States
+1 (844)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 3530 John Hopkins Court
  • San Diego, CA 92121
  • United States
+1 (844)

ImmunityBio Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ImmunityBio Stock Performance

As of 13-Nov-2026, ImmunityBio’s stock price is $6.01. Its current market cap is $6.4B with 1.06B shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$6.01 $6.07 $1.95 - $12.43 $6.4B 1.06B 12.5M -$1.06

ImmunityBio Financials Summary

As of 30-Sep-2026, ImmunityBio has a trailing 12-month revenue of $183M.

In Thousands,
USD 		TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 10,461,412 2,235,577 2,495,552 3,880,423
Revenue 182,572 113,288 14,745 622
EBITDA (981,603) (226,246) (266,751) (479,440)
Net Income (1,109,654) (351,398) (413,564) (583,196)
Total Assets 609,391 501,898 382,933 504,452
Total Debt 869,519 518,075 504,166 726,723
Public Fundamental Data provided by Morningstar, Inc. disclaimer

ImmunityBio Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore ImmunityBio‘s full profile, request access.

Request a free trial

ImmunityBio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies des
Drug Discovery
San Diego, CA
691 As of 2025

Boston, MA
 

Lexington, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ImmunityBio Competitors (63)

One of ImmunityBio’s 63 competitors is Aura Biosciences, a Formerly VC-backed company based in Boston, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Aura Biosciences Formerly VC-backed Boston, MA
Agenus Formerly VC-backed Lexington, MA
Iovance Biotherapeutics Corporation San Carlos, CA
Precigen Formerly VC-backed Germantown, MD
Affimed Formerly VC-backed Mannheim, Germany
You’re viewing 5 of 63 competitors. Get the full list »

ImmunityBio Patents

  • 1,641

    Total Documents Applications and Grants

  • Total Patents Families

  • 846

    Granted

  • 352

    Pending

  • Expiring in next 12 mo

ImmunityBio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026236689-A1 Intranasal adenovirus-5 influenza vaccine Pending 09-May-2025
WO-2026213319-A1 Nk-92 cells with hypoimmunogenic modifications Pending 03-Apr-2025
WO-2026196038-A1 Compositions and methods for nk-92 cells expressing native cd16 Pending 20-Mar-2025
GB-202503470-D0 Cell-mediated transient delivery of immune-enhancing molecules into the tumor microenvironment Inactive 10-Mar-2025
US-20260265327-A1 Anktiva and lymphocyte rescue compositions and methods Pending 07-Mar-2025 C07K14/5443
To view ImmunityBio’s complete patent history, request access »

ImmunityBio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ImmunityBio Investments & Acquisitions (8)

ImmunityBio’s most recent deal was a Joint Venture with Joint Venture (Amyris / ImmunityBio). The deal was made on 03-Jan-2022.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Joint Venture (Amyris / ImmunityBio) 03-Jan-2022 Joint Venture Drug Discovery
NantKwest 09-Mar-2021 Merger/Acquisition Drug Discovery
Altor BioScience 01-Aug-2017 Merger/Acquisition Drug Discovery
Liquid Genomics 31-Mar-2017 Merger/Acquisition Other Pharmaceuticals and Biotechnology
GlobeImmune 23-Mar-2017 Merger/Acquisition Biotechnology
You’re viewing 5 of 8 investments and acquisitions. Get the full list »

ImmunityBio ESG

Risk Overview

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view ImmunityBio’s complete esg history, request access »

ImmunityBio Affiliates

Subsidiaries (2)

Name Industry Location Year Founded
GlobeImmune Louisville, CO 1995
VBC Holdings

ImmunityBio FAQs

  • When was ImmunityBio founded?

    ImmunityBio was founded in 2014.

  • Where is ImmunityBio headquartered?

    ImmunityBio is headquartered in San Diego, CA.

  • What is the size of ImmunityBio?

    ImmunityBio has 691 total employees.

  • What industry is ImmunityBio in?

    ImmunityBio’s primary industry is Drug Discovery.

  • Is ImmunityBio a private or public company?

    ImmunityBio is a Public company.

  • What is ImmunityBio’s stock symbol?

    The ticker symbol for ImmunityBio is IBRX.

  • What is the current stock price of ImmunityBio?

    As of 13-Nov-2026 the stock price of ImmunityBio is $6.01.

  • What is the current market cap of ImmunityBio?

    The current market capitalization of ImmunityBio is $6.4B.

  • What is ImmunityBio’s current revenue?

    The trailing twelve month revenue for ImmunityBio is $183M.

  • Who are ImmunityBio’s competitors?

    Aura Biosciences, Agenus, Iovance Biotherapeutics, Precigen, and Affimed are some of the 63 competitors of ImmunityBio.

  • What is ImmunityBio’s annual earnings per share (EPS)?

    ImmunityBio’s EPS for 12 months was -$1.06.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process